Share information
248.40 €
-7.90 %
26/02/2026 17:37
-7.90 %
Open
High
Low
Volume
260.00 €
268.30 €
248.40 €
523,011
Latest News
26-Feb-2026
Strong Execution Fueling Sustained Company Growth
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
30-Jan-2026
KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)
13-Jan-2026
Innovation and Execution Power UCB’s Success